Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung disease.

Saavedra MT, Hughes GJ, Sanders LA, Carr M, Rodman DM, Coldren CD, Geraci MW, Sagel SD, Accurso FJ, West J, Nick JA.

Am J Respir Crit Care Med. 2008 Nov 1;178(9):929-38. doi: 10.1164/rccm.200803-387OC. Epub 2008 Aug 21.

2.

Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis.

Nick JA, Sanders LA, Ickes B, Briones NJ, Caceres SM, Malcolm KC, Brayshaw SJ, Chacon CS, Barboa CM, Jones MC, St Clair C, Taylor-Cousar JL, Nichols DP, Sagel SD, Strand M, Saavedra MT.

Thorax. 2013 Oct;68(10):929-37. doi: 10.1136/thoraxjnl-2012-202278. Epub 2013 Jun 19.

PMID:
23783371
3.

Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects.

Sloane AJ, Lindner RA, Prasad SS, Sebastian LT, Pedersen SK, Robinson M, Bye PT, Nielson DW, Harry JL.

Am J Respir Crit Care Med. 2005 Dec 1;172(11):1416-26. Epub 2005 Sep 15.

PMID:
16166615
4.

Evaluation of genome-wide expression profiles of blood and sputum neutrophils in cystic fibrosis patients before and after antibiotic therapy.

Conese M, Castellani S, Lepore S, Palumbo O, Manca A, Santostasi T, Polizzi AM, Copetti M, Di Gioia S, Casavola V, Guerra L, Diana A, Montemurro P, Mariggiò MA, Gallo C, Maffione AB, Carella M.

PLoS One. 2014 Aug 1;9(8):e104080. doi: 10.1371/journal.pone.0104080. eCollection 2014.

5.

Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.

Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ Jr.

Am J Respir Crit Care Med. 2010 Nov 1;182(9):1137-43. doi: 10.1164/rccm.201001-0057OC. Epub 2010 Jun 25.

6.

Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis.

Amadori A, Antonelli A, Balteri I, Schreiber A, Bugiani M, De Rose V.

Respir Med. 2009 Mar;103(3):407-13. doi: 10.1016/j.rmed.2008.09.024. Epub 2008 Nov 22.

7.

Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis.

Waters V, Atenafu EG, Salazar JG, Lu A, Yau Y, Matukas L, Tullis E, Ratjen F.

J Cyst Fibros. 2012 Jan;11(1):8-13. doi: 10.1016/j.jcf.2011.07.008. Epub 2011 Aug 16.

8.

Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.

Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH.

Am J Respir Crit Care Med. 2010 Sep 1;182(5):627-32. doi: 10.1164/rccm.200909-1421OC. Epub 2010 May 12.

PMID:
20463179
9.

Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation.

Horsley AR, Davies JC, Gray RD, Macleod KA, Donovan J, Aziz ZA, Bell NJ, Rainer M, Mt-Isa S, Voase N, Dewar MH, Saunders C, Gibson JS, Parra-Leiton J, Larsen MD, Jeswiet S, Soussi S, Bakar Y, Meister MG, Tyler P, Doherty A, Hansell DM, Ashby D, Hyde SC, Gill DR, Greening AP, Porteous DJ, Innes JA, Boyd AC, Griesenbach U, Cunningham S, Alton EW.

Thorax. 2013 Jun;68(6):532-9. doi: 10.1136/thoraxjnl-2012-202538. Epub 2013 Feb 9.

PMID:
23396354
10.

Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.

Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH.

Pediatr Pulmonol. 2010 Feb;45(2):127-34. doi: 10.1002/ppul.21117. Erratum in: Pediatr Pulmonol. 2010 May;45(5):521-2.

PMID:
20054859
11.

Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study.

Ordoñez CL, Stulbarg M, Grundland H, Liu JT, Boushey HA.

Pediatr Pulmonol. 2001 Jul;32(1):29-37.

PMID:
11416873
12.

Analysis of inflammatory and immune response biomarkers in sputum and exhaled breath condensate by a multi-parametric biochip array in cystic fibrosis.

Colombo C, Faelli N, Tirelli AS, Fortunato F, Biffi A, Claut L, Cariani L, Daccò V, Prato R, Conese M.

Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2):423-32.

PMID:
21658316
13.

Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.

de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, Paterson N, Jackson M, Lougheed MD, Kumar V, Aaron SD.

Thorax. 2011 Aug;66(8):680-5. doi: 10.1136/thx.2011.161117. Epub 2011 Jun 15.

PMID:
21680566
14.

Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation.

Moore DF, Li H, Jeffries N, Wright V, Cooper RA Jr, Elkahloun A, Gelderman MP, Zudaire E, Blevins G, Yu H, Goldin E, Baird AE.

Circulation. 2005 Jan 18;111(2):212-21. Epub 2005 Jan 3.

15.

Serum KL-6 as a novel disease marker in adolescent and adult cystic fibrosis.

Ohshimo S, Bonella F, Grammann N, Starke K, Cui A, Bauer PC, Teschler H, Kohno N, Guzman J, Costabel U.

Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(1):47-53.

PMID:
19960788
16.

Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations.

Sanders DB, Rosenfeld M, Mayer-Hamblett N, Stamey D, Redding GJ.

Pediatr Pulmonol. 2008 Nov;43(11):1142-6. doi: 10.1002/ppul.20924.

PMID:
18846562
17.

Effect of systemic inflammation on inspiratory and limb muscle strength and bulk in cystic fibrosis.

Dufresne V, Knoop C, Van Muylem A, Malfroot A, Lamotte M, Opdekamp C, Deboeck G, Cassart M, Stallenberg B, Casimir G, Duchateau J, Estenne M.

Am J Respir Crit Care Med. 2009 Jul 15;180(2):153-8. doi: 10.1164/rccm.200802-232OC. Epub 2009 Apr 2.

PMID:
19342416
18.

Plasma biomarkers and cystic fibrosis lung disease.

Cantin AM, Bilodeau G, Larivée P, Richter MV.

Clin Invest Med. 2012 Jul 4;35(4):E173-81.

PMID:
22863555
19.

Increase in exhaled carbon monoxide during exacerbations of cystic fibrosis.

Antuni JD, Kharitonov SA, Hughes D, Hodson ME, Barnes PJ.

Thorax. 2000 Feb;55(2):138-42.

20.

Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, Johnson CA; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2007 Aug;151(2):134-9, 139.e1. Epub 2007 Jun 22.

PMID:
17643762
Items per page

Supplemental Content

Write to the Help Desk